Covered recipient · General Payments record
L MICHAEL WEISS
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$1,274.18
71 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,259.36 | 70 |
| Education | $14.82 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie Inc. | $424.23 | 24 |
| Janssen Biotech, Inc. | $170.29 | 7 |
| Takeda Pharmaceuticals U.S.A., Inc. | $166.84 | 8 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $136.39 | 13 |
| PFIZER INC. | $101.93 | 5 |
| Celgene Corporation | $73.81 | 4 |
| Ironwood Pharmaceuticals, Inc | $44.64 | 2 |
| Regeneron Healthcare Solutions, Inc. | $31.37 | 2 |
| Fresenius Kabi USA, LLC | $24.00 | 1 |
| Exact Sciences Corporation | $23.23 | 1 |
| Gilead Sciences, Inc. | $22.44 | 1 |
| INTERCEPT PHARMACEUTICALS, INC. | $21.36 | 1 |
| Lilly USA, LLC | $19.45 | 1 |
| Ferring Pharmaceuticals Inc. | $14.20 | 1 |
Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
L MICHAEL WEISS
NPI 1215026158 · CMS profile ID 145469
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
CLEARWATER, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1215026158?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- L MICHAEL WEISS, NPI 1215026158, CMS profile ID 145469. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215026158?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). L MICHAEL WEISS, NPI 1215026158, CMS profile ID 145469. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215026158?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- L MICHAEL WEISS, NPI 1215026158, CMS profile ID 145469, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1215026158?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
71 matching records · $1,274.18 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–71 of 71.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $0.91 | 05/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057063611 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $5.35 | 05/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057225771 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $6.87 | 05/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057375489 | CMS |
| AbbVie Inc. | $17.58 | 05/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999579239 | CMS |
| AbbVie Inc. | $29.37 | 05/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999579233 | CMS |
| PFIZER INC. | $23.23 | 05/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050556743 | CMS |
| Janssen Biotech, Inc. | $23.44 | 05/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988078254 | CMS |
| Ironwood Pharmaceuticals, Inc | $25.87 | 05/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1045573335 | CMS |
| Celgene Corporation | $20.69 | 04/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015559593 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $5.85 | 04/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057334887 | CMS |
| AbbVie Inc. | $17.08 | 04/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999579227 | CMS |
| Fresenius Kabi USA, LLC | $24.00 | 04/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060094083 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.62 | 04/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057450081 | CMS |
| AbbVie Inc. | $22.33 | 04/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999579221 | CMS |
| AbbVie Inc. | $18.92 | 03/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999579217 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $14.67 | 03/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055664293 | CMS |
| Celgene Corporation | $15.52 | 03/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015559585 | CMS |
| AbbVie Inc. | $9.53 | 03/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999579211 | CMS |
| Ferring Pharmaceuticals Inc. | $14.20 | 02/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044255453 | CMS |
| Ironwood Pharmaceuticals, Inc | $18.77 | 02/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1045538377 | CMS |
| Janssen Biotech, Inc. | $24.29 | 01/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988078241 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $285,899.86 | 90 |
| PY2024 | Principal investigator | $338,643.08 | 85 |
| PY2023 | Recipient | $859.89 | 1 |
| PY2023 | Principal investigator | $240,205.84 | 74 |
| PY2022 | Principal investigator | $82,420.84 | 46 |
| PY2021 | Principal investigator | $122,620.13 | 34 |
| PY2020 | Principal investigator | $270,128.12 | 134 |
| PY2019 | Recipient | $8,000.00 | 1 |
| PY2019 | Principal investigator | $322,477.22 | 92 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
90 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $157.00 | 12/19/2025 | Non-covered Recipient Entity W Ctrl Gastroenterology Llp | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175188472 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,490.64 | 12/19/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223289946 |
| Principal investigator 1 | Janssen Research & Development, LLC | $157.00 | 12/17/2025 | Non-covered Recipient Entity W Ctrl Gastroenterology Llp | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175188186 |
| Principal investigator 1 | Janssen Research & Development, LLC | $959.00 | 12/17/2025 | Non-covered Recipient Entity W Ctrl Gastroenterology Llp | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175188534 |
| Principal investigator 1 | Janssen Research & Development, LLC | $348.00 | 12/12/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175345611 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,500.00 | 12/10/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223289438 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $38.00 | 12/10/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223289440 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,550.00 | 12/10/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223289448 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,550.00 | 12/10/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223289450 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $38.00 | 12/10/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223289454 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,550.00 | 12/10/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223289462 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,500.00 | 12/10/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223289474 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $38.00 | 12/10/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223289476 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,747.00 | 12/10/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223289478 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,686.00 | 12/10/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223289480 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $919.00 | 12/10/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223289482 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $919.00 | 12/10/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223289484 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,125.00 | 12/10/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223289486 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,500.00 | 12/05/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY | ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE | No dispute reported | 06/30/2026 | 1223289338 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,701.00 | 12/04/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211684824 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,426.92 | 12/04/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223289212 |
| Principal investigator 1 | Genentech, Inc. | $6,256.00 | 11/25/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211684836 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,738.80 | 11/25/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223288707 |
| Principal investigator 1 | Genentech, Inc. | $2,390.00 | 11/14/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211684834 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,426.92 | 11/14/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223288295 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,550.00 | 11/12/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223288185 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,550.00 | 11/12/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223288187 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,686.00 | 11/12/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223288189 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,125.00 | 11/12/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223288191 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $183.00 | 11/12/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223288193 |
| Principal investigator 1 | Genentech, Inc. | $1,618.00 | 11/07/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211684838 |
| Principal investigator 1 | Genentech, Inc. | $1,926.00 | 10/29/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211684830 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,025.84 | 10/29/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223287719 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,975.00 | 10/23/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175345618 |
| Principal investigator 1 | Genentech, Inc. | $10,113.00 | 10/16/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211684832 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,426.92 | 10/16/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223287033 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $183.00 | 10/08/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223286475 |
| Principal investigator 1 | Bausch Health US, LLC | $1,279.00 | 10/06/2025 | Non-covered Recipient Entity West Central Gastroenterology, LLP | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224848387 |
| Principal investigator 1 | Celgene Corporation | $2,700.00 | 10/06/2025 | Non-covered Recipient Entity Gastro Health Central Broward | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. | No dispute reported | 06/30/2026 | 1222304599 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,549.22 | 10/03/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223286269 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,550.00 | 10/02/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223286209 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,550.00 | 10/02/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223286211 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,550.00 | 10/02/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223286213 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,500.00 | 10/02/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223286215 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,125.00 | 10/02/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223286217 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,398.00 | 09/29/2025 | Non-covered Recipient Entity W Ctrl Gastroenterology Llp | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175188378 |
| Principal investigator 1 | Janssen Research & Development, LLC | $174.00 | 09/22/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175345585 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $4,213.00 | 09/18/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211684820 |
| Principal investigator 1 | Celgene Corporation | $6,800.00 | 09/10/2025 | Non-covered Recipient Entity Gastro Health Central Broward | A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. | No dispute reported | 06/30/2026 | 1222304585 |
| Principal investigator 1 | Bausch Health US, LLC | $2,069.00 | 09/03/2025 | Non-covered Recipient Entity West Central Gastroenterology, LLP | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224848349 |
| Principal investigator 1 | Bausch Health US, LLC | $1,198.00 | 09/03/2025 | Non-covered Recipient Entity West Central Gastroenterology, LLP | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224848352 |
| Principal investigator 1 | Janssen Research & Development, LLC | $157.00 | 08/28/2025 | Non-covered Recipient Entity W Ctrl Gastroenterology Llp | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175188174 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,341.00 | 08/26/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211684822 |
| Principal investigator 1 | Janssen Research & Development, LLC | $174.00 | 08/20/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175345595 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,343.00 | 08/07/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211684818 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,149.00 | 07/24/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175345566 |
| Principal investigator 1 | Bausch Health US, LLC | $1,593.00 | 07/23/2025 | Non-covered Recipient Entity West Central Gastroenterology, LLP | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224848345 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $6,650.00 | 07/22/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211684816 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,494.16 | 07/22/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223282896 |
| Principal investigator 1 | Eli Lilly and Company | $1,000.00 | 07/09/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | MIRIKIZUMAB LY3074828 PRO UC CD - OMVOH - ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187893326 |
| Principal investigator 1 | Bausch Health US, LLC | $371.00 | 07/07/2025 | Non-covered Recipient Entity West Central Gastroenterology, LLP | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224848357 |
| Principal investigator 1 | Genentech, Inc. | $1,812.00 | 06/19/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211684826 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,577.34 | 06/12/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223281176 |
| Principal investigator 1 | Bausch Health US, LLC | $1,492.00 | 06/02/2025 | Non-covered Recipient Entity West Central Gastroenterology, LLP | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224848361 |
| Principal investigator 1 | Bausch Health US, LLC | $371.00 | 06/02/2025 | Non-covered Recipient Entity West Central Gastroenterology, LLP | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224848367 |
| Principal investigator 1 | Bausch Health US, LLC | $1,198.00 | 06/02/2025 | Non-covered Recipient Entity West Central Gastroenterology, LLP | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224848372 |
| Principal investigator 1 | Genentech, Inc. | $8,302.00 | 05/27/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211684828 |
| Principal investigator 1 | Janssen Research & Development, LLC | $348.00 | 05/23/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175345627 |
| Principal investigator 1 | Janssen Research & Development, LLC | $174.00 | 04/17/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175345558 |
| Principal investigator 1 | Bausch Health US, LLC | $1,548.00 | 04/02/2025 | Non-covered Recipient Entity West Central Gastroenterology, LLP | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224848363 |
| Principal investigator 1 | Bausch Health US, LLC | $371.00 | 04/02/2025 | Non-covered Recipient Entity West Central Gastroenterology, LLP | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224848377 |
| Principal investigator 1 | Bausch Health US, LLC | $137.00 | 04/02/2025 | Non-covered Recipient Entity West Central Gastroenterology, LLP | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224848382 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,304.00 | 03/27/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175345634 |
| Principal investigator 1 | Janssen Research & Development, LLC | $157.00 | 03/20/2025 | Non-covered Recipient Entity W Ctrl Gastroenterology Llp | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175188442 |
| Principal investigator 1 | Janssen Research & Development, LLC | $279.00 | 03/20/2025 | Non-covered Recipient Entity W Ctrl Gastroenterology Llp | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175188517 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,418.00 | 03/20/2025 | Non-covered Recipient Entity W Ctrl Gastroenterology Llp | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175188614 |
| Principal investigator 1 | PFIZER INC. | $5,052.90 | 03/19/2025 | Non-covered Recipient Entity West Central Gastroenterology LLP | A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228775144 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,683.22 | 02/25/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223275527 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,538.00 | 02/21/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175345603 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,303.96 | 02/18/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223275353 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,762.00 | 02/11/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223275037 |
| Principal investigator 1 | Bausch Health US, LLC | $1,492.00 | 02/07/2025 | Non-covered Recipient Entity West Central Gastroenterology, LLP | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224848341 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $61,858.00 | 02/06/2025 | Non-covered Recipient Entity Gastro Florida | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | No dispute reported | 06/30/2026 | 1235997227 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,308.48 | 02/05/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223274763 |
| Principal investigator 1 | PFIZER INC. | $1,515.00 | 02/03/2025 | Non-covered Recipient Entity West Central Gastroenterology LLP | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228775243 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,159.06 | 01/21/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223274241 |
| Principal investigator 1 | Janssen Research & Development, LLC | $174.00 | 01/20/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175345578 |
| Principal investigator 1 | Bausch Health US, LLC | $1,198.00 | 01/08/2025 | Non-covered Recipient Entity West Central Gastroenterology, LLP | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224848333 |
| Principal investigator 1 | Bausch Health US, LLC | $371.00 | 01/08/2025 | Non-covered Recipient Entity West Central Gastroenterology, LLP | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224848336 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,995.48 | 01/07/2025 | Non-covered Recipient Entity WEST CENTRAL GASTROENTEROLOGY LLP | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223273621 |